Last reviewed · How we verify
Prednisone or Prednisolone
Prednisone and prednisolone are corticosteroids that suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisone and prednisolone are corticosteroids that suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Adrenocortical insufficiency, Rheumatoid arthritis, Systemic lupus erythematosus.
At a glance
| Generic name | Prednisone or Prednisolone |
|---|---|
| Also known as | Prednisone, prednisolone, corticosteroids |
| Sponsor | Sanofi |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | Phase 3 |
Mechanism of action
These synthetic glucocorticoids mimic cortisol and bind to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene expression. They inhibit phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppress T-cell and B-cell proliferation. This broad immunosuppressive and anti-inflammatory action makes them effective across multiple inflammatory and autoimmune conditions.
Approved indications
- Adrenocortical insufficiency
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Asthma and chronic obstructive pulmonary disease
- Allergic reactions
- Inflammatory bowel disease
- Organ transplant rejection prophylaxis
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Increased appetite
- Mood changes (euphoria, anxiety, depression)
- Osteoporosis (with chronic use)
- Immunosuppression / increased infection risk
- Gastrointestinal upset
- Acne
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone or Prednisolone CI brief — competitive landscape report
- Prednisone or Prednisolone updates RSS · CI watch RSS
- Sanofi portfolio CI